Skip to content

Study · Animal study (in vivo) · mouse · 2026

18 results

Generation and characterisation of a humanised GLP-1 receptor mouse model for translational drug development.

Sonne N, Roque M, Zachariassen LF, Porsgaard T, Pors SE, Cavalera M, Jones C, Osborn O, Thorbek DD, Riis ML, Feigh M, Quinn K and 4 more

Show all authors

Gaidarov I, Anthony T, Hansen HH, Tozzi M

EBioMedicine16 Jan 2026Cited by 4 (Europe PMC)

PMID41547115 (opens in a new tab)PMCIDPMC12855590 (opens in a new tab)DOI10.1016/j.ebiom.2026.106121 (opens in a new tab)PepBankPUB-41547115
Read at sourcePubMedAsk about this study
Jump to 18 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study18

18 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In lean hGLP1R mice, orforglipron significantly reduced body weight.

    In plain wordsIn mice with human GLP1R, orforglipron reduced body weight.

    Peptide
    Orforglipron
    Outcome
    DecreaseBody weight in lean mice
    Study

    mousen: not reported in source

    hGLP1R mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In lean hGLP1R mice, both semaglutide and orforglipron significantly reduced body weight and food intake, improved glucose tolerance, and induced taste aversion.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In lean hGLP1R mice, semaglutide significantly reduced body weight.

    In plain wordsIn mice with human GLP1R, semaglutide reduced body weight.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight in lean mice
    Study

    mousen: not reported in source

    hGLP1R mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In lean hGLP1R mice, both semaglutide and orforglipron significantly reduced body weight and food intake, improved glucose tolerance, and induced taste aversion.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In lean hGLP1R mice, orforglipron significantly reduced food intake.

    In plain wordsIn mice with human GLP1R, orforglipron reduced food intake.

    Peptide
    Orforglipron
    Outcome
    DecreaseFood intake in lean mice
    Study

    mousen: not reported in source

    hGLP1R mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In lean hGLP1R mice, both semaglutide and orforglipron significantly reduced body weight and food intake, improved glucose tolerance, and induced taste aversion.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In lean hGLP1R mice, semaglutide significantly reduced food intake.

    In plain wordsIn mice with human GLP1R, semaglutide reduced food intake.

    Peptide
    Semaglutide
    Outcome
    DecreaseFood intake in lean mice
    Study

    mousen: not reported in source

    hGLP1R mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In lean hGLP1R mice, both semaglutide and orforglipron significantly reduced body weight and food intake, improved glucose tolerance, and induced taste aversion.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In lean hGLP1R mice, orforglipron improved glucose tolerance.

    In plain wordsIn mice with human GLP1R, orforglipron improved glucose tolerance.

    Peptide
    Orforglipron
    Outcome
    IncreaseGlucose tolerance
    Study

    mousen: not reported in source

    hGLP1R mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In lean hGLP1R mice, both semaglutide and orforglipron significantly reduced body weight and food intake, improved glucose tolerance, and induced taste aversion.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In lean hGLP1R mice, semaglutide improved glucose tolerance.

    In plain wordsIn mice with human GLP1R, semaglutide improved glucose tolerance.

    Peptide
    Semaglutide
    Outcome
    IncreaseGlucose tolerance
    Study

    mousen: not reported in source

    hGLP1R mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In lean hGLP1R mice, both semaglutide and orforglipron significantly reduced body weight and food intake, improved glucose tolerance, and induced taste aversion.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.
  7. 07AnimalAnimal study (in vivo)Safety outcome

    In lean hGLP1R mice, orforglipron induced taste aversion.

    In plain wordsIn mice with human GLP1R, orforglipron induced taste aversion.

    Peptide
    Orforglipron
    Outcome
    IncreaseTaste aversion
    Study

    mousen: not reported in source

    hGLP1R mice
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In lean hGLP1R mice, both semaglutide and orforglipron significantly reduced body weight and food intake, improved glucose tolerance, and induced taste aversion.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.
  8. 08AnimalAnimal study (in vivo)Safety outcome

    In lean hGLP1R mice, semaglutide induced taste aversion.

    In plain wordsIn mice with human GLP1R, semaglutide induced taste aversion.

    Peptide
    Semaglutide
    Outcome
    IncreaseTaste aversion
    Study

    mousen: not reported in source

    hGLP1R mice
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In lean hGLP1R mice, both semaglutide and orforglipron significantly reduced body weight and food intake, improved glucose tolerance, and induced taste aversion.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In mice, orforglipron and semaglutide showed overlapping brain c-Fos activation patterns.

    In plain wordsIn mice, orforglipron showed brain activation patterns that overlapped with semaglutide patterns.

    Peptide
    Orforglipron
    Outcome
    Not applicableBrain c-Fos activation patterns
    Study

    mousen: not reported in source

    hGLP1R mice
    Comparator
    Semaglutide
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    CNS response profiles were evaluated using high-resolution 3D whole-brain imaging, revealing overlapping c-Fos activation patterns for both agonists.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In mice, semaglutide and orforglipron showed overlapping brain c-Fos activation patterns.

    In plain wordsIn mice, semaglutide showed brain activation patterns that overlapped with orforglipron patterns.

    Peptide
    Semaglutide
    Outcome
    Not applicableBrain c-Fos activation patterns
    Study

    mousen: not reported in source

    hGLP1R mice
    Comparator
    Orforglipron
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    CNS response profiles were evaluated using high-resolution 3D whole-brain imaging, revealing overlapping c-Fos activation patterns for both agonists.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In DIO hGLP1R mice, chronic orforglipron reduced body weight.

    In plain wordsIn obese mice with human GLP1R, chronic orforglipron reduced body weight.

    Peptide
    Orforglipron
    Outcome
    DecreaseBody weight in obese mice
    Study

    mousen: not reported in source

    DIO hGLP1R mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In DIO hGLP1R mice, chronic administration of either compound produced robust reductions in body weight, food intake and plasma lipids.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In DIO hGLP1R mice, chronic semaglutide reduced body weight.

    In plain wordsIn obese mice with human GLP1R, chronic semaglutide reduced body weight.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight in obese mice
    Study

    mousen: not reported in source

    DIO hGLP1R mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In DIO hGLP1R mice, chronic administration of either compound produced robust reductions in body weight, food intake and plasma lipids.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In DIO hGLP1R mice, chronic orforglipron reduced food intake.

    In plain wordsIn obese mice with human GLP1R, chronic orforglipron reduced food intake.

    Peptide
    Orforglipron
    Outcome
    DecreaseFood intake in obese mice
    Study

    mousen: not reported in source

    DIO hGLP1R mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In DIO hGLP1R mice, chronic administration of either compound produced robust reductions in body weight, food intake and plasma lipids.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In DIO hGLP1R mice, chronic semaglutide reduced food intake.

    In plain wordsIn obese mice with human GLP1R, chronic semaglutide reduced food intake.

    Peptide
    Semaglutide
    Outcome
    DecreaseFood intake in obese mice
    Study

    mousen: not reported in source

    DIO hGLP1R mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In DIO hGLP1R mice, chronic administration of either compound produced robust reductions in body weight, food intake and plasma lipids.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.
  15. 15AnimalAnimal study (in vivo)Efficacy outcome

    In DIO hGLP1R mice, chronic orforglipron reduced plasma lipids.

    In plain wordsIn obese mice with human GLP1R, chronic orforglipron reduced blood lipids.

    Peptide
    Orforglipron
    Outcome
    DecreasePlasma lipids
    Study

    mousen: not reported in source

    DIO hGLP1R mice
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In DIO hGLP1R mice, chronic administration of either compound produced robust reductions in body weight, food intake and plasma lipids.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.
  16. 16AnimalAnimal study (in vivo)Efficacy outcome

    In DIO hGLP1R mice, chronic semaglutide reduced plasma lipids.

    In plain wordsIn obese mice with human GLP1R, chronic semaglutide reduced blood lipids.

    Peptide
    Semaglutide
    Outcome
    DecreasePlasma lipids
    Study

    mousen: not reported in source

    DIO hGLP1R mice
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In DIO hGLP1R mice, chronic administration of either compound produced robust reductions in body weight, food intake and plasma lipids.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.
  17. 17AnimalAnimal study (in vivo)Activity measurement

    In WT mice, orforglipron was inactive.

    In plain wordsIn wild-type mice, orforglipron was inactive.

    Peptide
    Orforglipron
    Outcome
    No significant changePharmacological response in WT mice
    Study

    mousen: not reported in source

    WT mice
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Notably, orforglipron was inactive in WT mice, which responded only to semaglutide.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.
  18. 18AnimalAnimal study (in vivo)Activity measurement

    WT mice responded to semaglutide but not orforglipron.

    In plain wordsIn wild-type mice, semaglutide produced a response, whereas orforglipron was inactive.

    Peptide
    Semaglutide
    Outcome
    Not applicablePharmacological response in WT mice
    Study

    mousen: not reported in source

    WT mice
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Notably, orforglipron was inactive in WT mice, which responded only to semaglutide.
    1 context sentence
    Summary · context
    The hGLP1R mouse model was pharmacologically characterised using peptide (semaglutide) and small-molecule (orforglipron) GLP1RAs in lean and diet-induced obese (DIO) hGLP1R and wild-type (WT) mice.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 2

    14 Oct 2026, 01:46 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.